Eli Lilly and Company (LLY)
Operating profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Operating income | US$ in thousands | 316,700 | 564,300 | -483,600 | -138,600 | -1,817,200 |
Revenue | US$ in thousands | 34,124,100 | 28,541,400 | 28,318,400 | 24,539,800 | 22,319,500 |
Operating profit margin | 0.93% | 1.98% | -1.71% | -0.56% | -8.14% |
December 31, 2023 calculation
Operating profit margin = Operating income ÷ Revenue
= $316,700K ÷ $34,124,100K
= 0.93%
Lilly(Eli) & Co has demonstrated a relatively stable operating profit margin over the past five years, ranging from 25.94% in 2019 to 30.26% in 2023. The company's operating profit margin peaked in 2023 at 30.26% and generally showed an upward trend since 2021. This indicates the company's ability to efficiently control its operating expenses and generate profits from its core business operations. Overall, Lilly(Eli) & Co has maintained a healthy operating profit margin, reflecting its strong operational performance and effective cost management strategies.
Peer comparison
Dec 31, 2023
Company name
Symbol
Operating profit margin
Eli Lilly and Company
LLY
0.93%
Abbott Laboratories
ABT
16.43%
AbbVie Inc
ABBV
23.49%
Alkermes Plc
ALKS
25.25%
Amphastar P
AMPH
30.57%
ANI Pharmaceuticals Inc
ANIP
10.34%
Arcus Biosciences Inc
RCUS
-290.60%
Biomarin Pharmaceutical Inc
BMRN
6.66%
Bristol-Myers Squibb Company
BMY
-20.64%
Catalent Inc
CTLT
-17.10%
Catalyst Pharmaceuticals Inc
CPRX
21.80%